COTA Secures $34M in Growth Capital and Triples Data Access to Better Serve Life Science Partners and Provider Institutions
Access to Over One Million Patient Data Records and Additional Funding Support Enhanced Real-World Data and Analytics Services in Oncology
Varian Medical Systems Invests in COTA, Inc. to Help Drive Faster, More Accurate Data-Driven Cancer Care
Varian has invested $20M in COTA. Together, the two companies will work to empower cancer clinics with curated RWD and analytics tools.
COTA Extends Research Collaboration Agreement With The U.S. Food and Drug Administration
COTA has extended its Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) for an additional three years. This renewed RCA will expand on the objective to explore the applications of real-world data in oncology.
New Findings Released – RWE Pilot 2.0 Project
Friends of Cancer Research leads collaborative effort including COTA and nine other organizations to advance the collective understanding in applications of real-world data. New findings reveal further insights in non-small cell lung cancer (NSCLC) with a particular focus on novel treatment strategies.
COTA’s Podcast Brings Together RWD Experts from Across the Industry
Real World Talk with COTA brings together thought leaders across the industry to discuss RWD and its impact on drug development and cancer care. Meet some of our recent guests…
Improving Patients’ Experiences and Outcomes with Technology and Real-World Data
Leading the data and digital team at Novartis, Bruno Villetelle believes that real world data should have a real world impact on patient care. He joins the #RealWorldTalk podcast to discuss how technology and data collection are being used at all stages of treatment to improve patients’ experiences and outcomes.
The Lancet Rheumatology Publishes Additional Findings on Tocilizumab, Fueled by Real-World Data
A recent observational study using real world data shows promising results from using tocilizumab in patients with severe COVID-19. According to study co-author Shivam Mathura, “While these results need to be further validated through clinical trials, we are thrilled to provide early insights to those in the field as we continue to fight this pandemic.”
COTA Featured in BioCentury – Real World Data’s Power to Increase Racial Diversity in Clinical Research
COTA’s Chief Medical Officer, Dr. C.K. Wang spoke with BioCentury to help further the conversation around the role of RWD in increasing racial diversity in clinical research.
COVID-19 Causes Delays in Cancer Detection, Patient Care
Real-world data is perhaps more important now than ever, but COVID-19 has thrown patient care and data gathering in oncology into chaos.
Supporting the Ratification of the Equal Rights Amendment
COTA is proud to share that we have joined a diverse group of 93 companies in signing an Amicus Brief to ratify the Equal Rights Amendment. By signing this Brief, COTA joins influential companies such as Apple, Biogen, Gilead Sciences and Pfizer, in demanding gender equality in the workplace and society at large.
